Remimazolam Improves the Safety in Elderly Patients Undergoing Gastrointestinal Endoscopy
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Gastroenteroscopy diagnosis and treatment drugs need to meet the needs of quick onset, quick
recovery and less anesthesia complications. Remimazolam is an anesthetic sedative
independently developed by China. It is a new short-acting GABA(A) receptor agonist.
Remimazolam has the advantages of rapid onset, rapid recovery, antagonist, controllable
degree of cardiovascular and respiratory depression, low incidence of hypotension and
respiratory depression. However, elderly patients as important and special patients, there
are still a lack of relevant studies and reports.
In order to verify the safety and effectiveness of remimazolam in the gastroenteroscopy
treatment of elderly patients, it can reduce the incidence of intraoperative hypotension or
respiratory depression rate, improve the quality of recovery of elderly patients.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University